The Company previously entered into a Down Payment Agreement with Hatchtech on November 20, 2025 (the "Down Payment Agreement"), pursuant to which the Company paid a $450,000 deposit to Hatchtech (th…
Effectively, the Company believes the 13 current API theoretical manufacturing capacity could be roughly doubled, if needed, due to one or more of the following: a higher than expected sales demand f…
As of March 31, 2026, three of the Company's wholesaler customers accounted for 92 % of its total gross accounts receivable balance at 39 %, 28 % and 25 %, respectively.
In December 2025, the Company announced that it had signed its first commercial agreement with a major Pharmacy Benefit Manager (“PBM”) to expand patient access for ZELSUVMI. This agreement is with a…
s, the Company determines if there are distinct performance obligations identified in the arrangement. The Company recognizes revenues from non-refundable, upfront fees allocated to the license when …
Pelthos Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PTHS-DEBT
Debt stack $52.9M
90%
Market cache reports total debt of $52.9M.
PTHS-DEBT-16132
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
PTHS-DEBT-60641
Warrants outstanding: 1362000
90%
xbrl warrant detail from xbrl 2026-03-31.
Pelthos Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Pelthos Therapeutics Inc..
Pelthos Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
PTHS-OWNER-MURCHINSON-LTD
Murchinson Ltd.
90%
13F overlay lists Murchinson Ltd. as top holder; 17 tracked holders.
Pelthos Therapeutics Inc. Extended Supply Chain Network
